Disclosed is a monoclonal anti-human CCL20 antibody or an antigen-binding portion thereof, comprising a heavy chain and a light chain, wherein the complementarity determining regions (CDRs) are as those defined in the specification. Also disclosed is its use for the treatment of a CCR6 associated condition.